Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2007-06-21
2010-02-02
Harris, Alana M. (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C530S300000, C530S327000, C530S328000, C514S002600, C514S015800
Reexamination Certificate
active
07655239
ABSTRACT:
Methods for the detection, monitoring and treatment of malignancies in which the HER-2
eu oncogene is associated are disclosed. Detection of specific T cell activation (e.g., by measuring the proliferation of T cells) in response to in vitro exposure to the HER-2
eu protein, or detection of immunocomplexes formed between the HER-2
eu protein and antibodies in body fluid, allows the diagnosis of the presence of a malignancy in which the HER-2
eu oncogene is associated. The present invention also discloses methods and compositions, including peptides, for treating such malignancies.
REFERENCES:
patent: 3766162 (1973-10-01), Spector
patent: 3791932 (1974-02-01), Schuurs et al.
patent: 3817837 (1974-06-01), Rubenstein et al.
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3901654 (1975-08-01), Gross
patent: 3935074 (1976-01-01), Rubenstein et al.
patent: 3984533 (1976-10-01), Uzgiris
patent: 3996345 (1976-12-01), Ullman et al.
patent: 4034074 (1977-07-01), Miles
patent: 4098876 (1978-07-01), Piasio et al.
patent: 4233402 (1980-11-01), Maggio et al.
patent: 4452901 (1984-06-01), Gordon et al.
patent: 5320947 (1994-06-01), Cheever et al.
patent: 5401638 (1995-03-01), Carney et al.
patent: 5550214 (1996-08-01), Eberlein et al.
patent: 5840839 (1998-11-01), Wang et al.
patent: 5958784 (1999-09-01), Benner
patent: 5985553 (1999-11-01), King et al.
patent: 6514942 (2003-02-01), Ioannides et al.
patent: 7402314 (2008-07-01), Sherman
patent: 7425606 (2008-09-01), Kosmatopoulos et al.
patent: WO 90/14357 (1990-11-01), None
patent: WO 91/02062 (1991-02-01), None
patent: WO 94/20127 (1994-09-01), None
Alper et al., “The Presence of c-erbB-2 Gene Product-related Protein in Culture Medium Conditioned by Breast Cancer Cell Line SK-BR-3,”Cell Growth&Differentiation1:591-599, 1990.
Bargmann et al., “The neu oncogene encodes an epidermal growth factor receptor-related protein,”Nature319:226-230, 1986.
Baselga et al., “Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185(HER2) Monoclonal Antibody in Patients With HER2
eu-Overexpressing Metastatic Breast Cancer,”Journal of Clinical Oncology14(3): 737-744, 1996.
Ben-Mahrez et al., “Circulating Antibodies Against C-myc Oncogene Product In Sera Of Colorectal Cancer Patients,” Int. J. Cancer 46: 35-38, 1990.
Bishop and Orosz, “Limiting Dilution Analysis For Alloreactive, TCGF-Secretory T Cells. Two Related LDA Methods That Discriminate Between Unstimulated Precursor T Cells and In Vivo-Alloactivated T Cells,” Transplantation 47(4): 671-677, 1989.
Bodmer, W., “T-Cell Immune Responses to Cancer—A New Look,” Human Immunology 30:259-261, 1991.
Bowen-Pope et al., “Production of platelet-derived growth factor-like molecules and reduced expression of platelet-derived growth factor receptors accompany transformation by a wide spectrum of agents,” Proc. Natl. Acad. Sci. USA 81: 2396-2400, 1984.
Brooks et al., “Human lymphocyte markers defined by antibodies derived from somatic cell hybrids,” Clin. Exp. Immunol. 39: 477-485, 1980.
Brown et al., “Protein Antigens of Normal and Malignant Human Cells Identified by Immunoprecipitation with Monoclonal Antibodies,” Journal of Biological Chemistry 255(11): 4980-4983, 1980.
Burnette et al., “Western Blotting: Electropheretic Transfer of Proteins from Sodium Dodecyl Sulfate-Polyacrylamide Gels to Unmodified Nitrocellulose and Radiographic Detection with Antibody and Radioiodinated Protein A,” Analytical Biochemistry 112: 195-203, 1981.
Coussens et al., “Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene,” Science 230: 1132-1139, 1985.
Dhut et al, “BCR-ABL and BCR Proteins: Biochemical Characterization and Localization,” Leukemia 4(11): 745-750, 1990.
Disis et al., “Existent T-Cell and Antibody Immunity to HER-2
eu Protein in Patients With Breast Cancer,” Cancer Res. 54: 16-20, 1994.
Disis, M.L. et al., “Immunity to the HER-2/Neu Oncogenic Protein”,Ciba Foundation Symposium,Amsterdam, NL, 187:198-211, 1994.
Disis, M.L. et al., “Immunization to Oncogenic HER-2
eu Protein With Peptide Based Vaccines”,Proc. Amer. Assn. for Cancer Research36:251(abstract 1498) Mar. 1995.
Falk et al., “Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules,” Nature 351: 290-296, 1991.
Feller and de la Cruz, “Identifying antigenic T-cell sites,” Nature 349: 720-721, 1991.
Fisk et al., “Oligopeptide Induction of a Cytotoxic T Lymphocyte Response to HER-2/Neu Proto-oncogene in Vitro,” Cellular Immunology 157:415-427, 1994.
Flanagan and Leder, “neu protooncogene fused to an immunoglobulin heavy chain gene requires immunoglobulin light chain for cell surface expression and oncogenic transformation,” Proc. Natl. Acad. Sci. USA 85: 8057-8061, 1998.
Igelhart et al., “Increased erbB-2 Gene Copies and Expression in Multiple Stages of Breast Cancer,” Cancer Research 50: 6701-6707, 1990.
Ioannides et al., “Antigens Recognized by T cells in Ovarian Cancer,” in Abstracts of the Fourth International Conference of Anticancer Research, Oct. 21-25, 1992, Rethymnon, Crete, Greece, p. 1870.
Ioannides et al., “CTL Clones Isolated from Ovarian Tumor Infiltrating Lymphocytes can Recognize Peptides with Sequences Corresponding to the HER2
eu Gene Product,” FASEB Journal 6: A1404, Abstract No. 2711, 1992.
Ioannides et al., “Cytotoxic T Cells Isolated From Ovarian Malignant Ascites Recognize a Peptide Derived From the HER-2
eu Proto-oncogene,” Cell. Immunol. 151: 225-234, 1993.
Ioannides et al., “Cytotoxic T-Cell Clones Isolated from Ovarian Tumour Infiltrating Lymphocytes Recognize Common Determinants on Non-Ovarian Tumour Clones,” Scand. J. Immunol. 37: 413-424, 1993.
Ioannides et al., “T-Cell Recognition of Oncogene Products: A New Strategy for Immunotherapy,” Molecular Carcinogenesis 6: 77-82, 1992.
Ioannides, Abstracts Fourth International Conference of Anticancer Research Oct. 21-25, 1992 p. 1870.
Ioannides, “Antigens and vaccines of female genital cancers (Meeting abstract),” Cancerlit Database Abstract No. ICDB/93690682, 1992.
Ioannides, et al., “Cytotoxic T Cells Isolated From Ovarian Malignant Ascites Recognize a Peptide Derived From the HER-2
eu Proto-oncogene,” Cell. Immunol. 151:225-234, 1993.
Ioannides, Society for Biological Therapy 1992 Annual Meeting, p. 27 Oct. 29-Nov. 1, 1992.
Kallioniemi et al., “ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization,” Proc. Natl. Acad. Sci. 89: 5321-5325, 1992.
Kerns et al., “c-erbB-2 Expression In Breast Cancer Detected by Immunoblotting and Immunohistochemistry,” Journal of Histochemistry and Cytochemistry 38(12): 1823-1830, 1990.
Laemmli, U., “Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4,” Nature 227: 680-685, 1970.
Leitzel et al., “Elevated Soluble c-erbB2 Antigen Levels in the Serum and Effusions of a Proportion of Breast Cancer Patients,” Journal of Clinical Oncology 10(9): 1436-1443, 1992.
Lichtenstein et al., “Effects of .beta.-2 Microglobulin Anti-sense oligonucleotides on Sensitivity of HER2
eu Oncogene-Expressing and Nonexpressing Target Cells to Lymphocyte-Mediated Lysis,” Cellular Immunology 141: 219-232, 1992.
Lippman, M., “Potential Contributions of Breast Cancer Biology to Management of Breast Cancer,” Advances in Oncology 8(3): 26-28, 1992.
Lippman, M., “Potential Contributions of Breast Cancer Biology to Management of Breast Cancer”, Advances in Oncology 8(3): 26-28, 1992.
Maguire and Greene, “The neu (c-erbB-2) Oncogene,” Seminars in Oncology 16(2): 148-155, 1989.
Margalit et al., “Prediction of Immunodomin
Cheever Martin A
Disis Mary L
Harris Alana M.
Holleran Anne L
Seed IP Law Group PLLC
University of Washington
LandOfFree
Immune reactivity to HER-2/ neu protein for diagnosis and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immune reactivity to HER-2/ neu protein for diagnosis and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immune reactivity to HER-2/ neu protein for diagnosis and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4228987